Evidence map›Paper›PMID 33124951›Full record

ArticleBioengineered2020

Prognostic and clinical significance of long non-coding RNA SNHG12 expression in various cancers.

Chenghao Zhang, Xiaolei Ren, Wenchao Zhang, Lile He, Lin Qi, Ruiqi Chen, Chao Tu, Zhihong Li

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Nucleolar Proteins and Non-Coding RNAs: Roles in Renal Cancer.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chenghao ZhangDepartment of Orthopedics, the Second Xiangya Hospital, Central South University , Changsha, China.
Xiaolei RenDepartment of Orthopedics, the Second Xiangya Hospital, Central South University , Changsha, China.
Wenchao ZhangDepartment of Orthopedics, the Second Xiangya Hospital, Central South University , Changsha, China.
Lile HeDepartment of Orthopedics, the Second Xiangya Hospital, Central South University , Changsha, China.
Lin QiDepartment of Orthopedics, the Second Xiangya Hospital, Central South University , Changsha, China.
Ruiqi ChenDepartment of Orthopedics, the Second Xiangya Hospital, Central South University , Changsha, China.
Chao TuDepartment of Orthopedics, the Second Xiangya Hospital, Central South University , Changsha, China.
Zhihong LiDepartment of Orthopedics, the Second Xiangya Hospital, Central South University , Changsha, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, increasing studies suggested that lncRNA SNHG12 was aberrantly expressed in kinds of cancers. However, definite prognostic value of SNHG12 remains unclear. We conducted this meta-analysis to evaluate the association between SNHG12 expression level and cancer prognosis. A literature retrieval was conducted by searching kinds of databases. The meta-analysis was performed by using Revman 5.2 and Stata 12.0 software. Besides, The Cancer Genome Atlas dataset was analyzed to validate the results in our meta-analysis via using Gene Expression Profiling Interactive Analysis. The pooled results showed that high SNHG12 expression significantly indicated worse overall survival and recurrence-free survival. Tumor type, sample size, survival analysis method, and cutoff value did not alter SNHG12 prognosis value according to stratified analysis results. Additionally, higher expression of SNHG12 suggested unfavorable clinicopathological outcomes including larger tumor size, lymph node metastasis, distant metastasis, and advanced clinical stage. Online cross-validation in TCGA dataset further indicated that cancer patients with upregulated SNHG12 expression had worse overall survival and disease-free survival. Therefore, elevated SNHG12 expression was associated with poor survival and unfavorable clinical outcomes in various cancers, and therefore might be a potential prognostic biomarker in human cancers.

Indexed as

Disease-Free SurvivalFemaleHumansMaleMiddle AgedPrognosisRNA, Long NoncodingSarcomaSoftwareRNA, Long NoncodingSNHG12 long non-coding RNA, humancancerLncRNAprognosissarcomaSNHG12

Identifiers

PMID33124951
PMCPMC8291808
OpenAlexW3096405833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.